罗曲普坦琥珀酸盐
|
|
|
- CAS号:
- 158930-17-7
- 英文名:
- Frova
- 英文别名:
- Frova;Migard;Miguard;Frovelan;Unii-D28J6W18hy;Frova，Frovatriptan Succinate;Frovatriptan succinate [usan];Frovatriptan (succinate salt);Frovatriptan succinate hydrate;Frovatriptan Succinate (1286413)
- 中文名:
- 罗曲普坦琥珀酸盐
- 中文别名:
- 夫罗曲坦琥珀酸;夫罗曲坦琥珀酸盐;罗曲普坦琥珀酸盐;琥珀酸夫罗曲坦一水合物;夫罗曲坦琥珀酸盐水合物;夫罗曲普坦琥珀酸盐水合物
- CBNumber:
- CB01247842
- 分子式:
- C18H25N3O6
- 分子量:
- 0
- MOL File:
- 158930-17-7.mol
|
|
|
罗曲普坦琥珀酸盐化学性质
-
熔点:
-
150-153°C
-
|
-
储存条件:
-
2-8°C
-
|
-
溶解度:
-
DMSO (Slightly), Methanol (Slightly, Heated), Water (Slightly, Heated)
-
|
-
形态:
-
powder
-
|
-
颜色:
-
white to beige
-
|
-
CAS 数据库:
-
158930-17-7
-
|
罗曲普坦琥珀酸盐性质、用途与生产工艺
Frovatriptan succinate hydrate ((R)-Frovatriptan succinate hydrate) 是一种强效，高亲和力，选择性和具有口服活性的 5-HT1B (pK50 为 8.2) 和 5-HT1D 受体激动剂，选择性是 5-HT1A，5-HT1F 和 5-HT7 的 10 倍以上，是其他 5-HT，多巴胺，组胺 H1 和 α1-肾上腺素受体的 1000 倍以上。Frovatriptan succinate hydrate 可用于偏头痛的研究。
|
5-HT
1B
Receptor
8.2 (pEC
50
)
|
5-HT
1D
Receptor
|
Cerebral vasodilatation and neurogenic inflammation are considered to be prime movers in the pathogenesis of migraine. Activation of 5-HT
1B
reverses cerebral vasodilatation and activation of 5-HT
1D
prevents neurogenic inflammation. Frovatriptan has a high affinity for 5-HT
1B
and 5-HT
1D
receptors and a moderate affinity for the 5-HT
1A
and 5-HT
1F
receptors subtypes. Frovatriptan has a moderate affinity for the 5-HT
7
receptors, an action associated with coronary artery relaxation in the dog.
Oral bioavailability of Frovatriptan is 22%-30% and is not affected by food. Although the maximum concentration in the plasma is achieved in 2-3 hours, 60%-70% of this is achieved in 1 hour. A steady state is achieved in 4-5 days. Plasma protein binding is low at 15%. The most unique feature is the relative terminal long half-life of about 26 hours. Frovatriptan is chiefly metabolized by CYP1A2 and is cleared by the kidney and liver making moderate failure of either organ not a limiting factor in treatment.
Frovatriptan (0.1, 0.2, and 0.3 mg/kg; a single bolus intraduodenal administration) treatment produces an increase in carotid vascular resistance, which is sustained for at least 5 hours in dogs.
罗曲普坦琥珀酸盐
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/04/30 | HY-B1658A | 罗曲普坦琥珀酸盐
Frovatriptan succinate hydrate | 158930-17-7 | 1mg | 304元 |
| 2024/04/30 | HY-B1658A | Frovatriptan succinate hydrate | | 5 mg | 620元 |
158930-17-7, 罗曲普坦琥珀酸盐 相关搜索:
- Pharmaceuticals
- Intermediates & Fine Chemicals
- Chiral Reagents
- C14H17N3OC4H6O4H2O
- 琥珀酸夫罗曲坦一水合物
- 夫罗曲坦琥珀酸盐水合物
- 夫罗曲坦琥珀酸盐
- 夫罗曲坦琥珀酸
- 罗曲普坦琥珀酸盐
- 夫罗曲普坦琥珀酸盐水合物
- 158930-17-7
- Serotonin Receptor,5-HT1D,5-HT Receptor,Frovatriptan succinate hydrate,orally,Inhibitor,SB 209509 succinate,menstrual,Frovatriptan succinate,(R)-Frovatriptan succinate,inhibit,5-HT7,5-hydroxytryptamine Receptor,vomiting,carotid,migraine,5-HT1B,VML 251 succinate,photophobia,phonophobia,vascular,nausea
- Frova，Frovatriptan Succinate
- Frovatriptan (succinate salt)
- Frovatriptan Succinate (1286413)
- Frovatriptan Succinate hydrateQ: What is
Frovatriptan Succinate hydrate Q: What is the CAS Number of
Frovatriptan Succinate hydrate Q: What is the storage condition of
Frovatriptan Succinate hydrate Q: What are the applications of
Frovatriptan Succinate hydrate
- (R)-3-(Methylamino)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide succinate hydrate
- Frovatriptan Succinate Monohydrate (10mM in DMSO)
- butanedioicacid,(6R)-6-(methylamino)-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide,hydrate
- Unii-D28J6W18hy
- Frovatriptan succinate hydrate
- Frovatriptan succinate [usan]
- Butanedioic acid, compd. with (R)-2,3,4,9-tetrahydro-3-(methylamino)-1H-carbazole-6-carboxamide (1:1), monohydrate
- 1H-Carbazole-6-carboxamide, 2,3,4,9-tetrahydro-3-(methylamino)-, (R)-, butanedioate (1:1), monohydrate
- Miguard
- Migard
- Frovelan
- Frovatriptan Succinate Monohydrate
- (3R)-2,3,4,9-Tetrahydro-3-(methylamino)-1H-carbazole-6-carboxamide Butanedioic Acid Monohydrate
- Frova